Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer.

The journal of pathology. Clinical research - 1 Jul 2021

Gonzalez David, Mateo Joaquin, Stenzinger Albrecht, Rojo Federico, Shiller Michelle, Wyatt Alexander W, Penault-Llorca Frédérique, Gomella Leonard G, Eeles Ros, Bjartell Anders

Abstract excerpt

Analysis of the genomic landscape of prostate cancer has identified different molecular subgroups with relevance for novel or existing targeted therapies. The recent approvals of the poly(ADP-ribose) polymerase (PARP) inhibitors olaparib and rucaparib in the metastatic castration-resistant prostate cancer (mCRPC) setting signal the need to embed molecular diagnostics in the clinical pathway of patients with mCRPC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Indoles
Share to Pathology, Molecular

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phthalazines

Share to Piperazines

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Prostatic Neoplasms

Share to Prostatic Neoplasms, Castration-Resistant

Share to Recombinational DNA Repair

Source

Open in PubMed Open full text

Identifiers

PMID: 33630412
DOI: 10.1002/cjp2.203
PMCID: PMC8185363

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer.PMID 33630412Read ↗

Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic.Semantic proximity Read ↗

Practical Guidance on Establishing a Molecular Testing Pathway for Alterations in Homologous Recombination Repair Genes in Clinical Practice for Patients with Metastatic Prostate CancerSemantic proximity Read ↗

Treatment strategies for DNA repair-deficient prostate cancer.Semantic proximity Read ↗

Clinical implications of genomic alterations in metastatic prostate cancer.Semantic proximity Read ↗

Clinical implications of homologous recombination repair mutations in prostate cancer.Semantic proximity Read ↗

Genetic and Genomic Testing for Prostate Cancer: Beyond DNA RepairSemantic proximity Read ↗

Durable benefit from poly(ADP-ribose) polymerase inhibitors in metastatic prostate cancer in routine practice: biomarker associations and implications for optimal clinical next-generation sequencing testingSemantic proximity Read ↗

Homologous Recombination Repair Gene Mutations in Prostate Cancer: Prevalence and Clinical Value.Semantic proximity Read ↗

Future directions for precision oncology in prostate cancerSemantic proximity Read ↗

PARP inhibitors for prostate cancerSemantic proximity Read ↗

Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2)Semantic proximity Read ↗

Toward Informed Selection and Interpretation of Clinical Genomic Tests in Prostate CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.